Document is current

Article History

Received: 8 March 2022

Accepted: 6 December 2022

First Online: 14 January 2023

Declarations

:

: HS: research funding from Astellas Pharma Inc., Taisho Toyama Pharmaceutical, Takeda Pharmaceutical, Novo Nordisk Pharma, Sanofi, Mitsubishi Tanabe Pharma Co., Novartis Pharma K.K., Shionogi Pharma Co., Ltd, Boehringer Ingelheim, AstraZeneca K.K. and MSD; honoraria from Shionogi Pharma Co., Mitsubishi Tanabe Pharma Co., Astellas Pharma Inc., Novartis Pharma K.K., Eli Lilly, Ono Pharmaceutical Co., MSD and Sanofi; YO: Honoraria/lecture fees from Ono Pharmaceutical, Novo Nordisk Pharm Ltd and Sumitomo Pharma; research funding from Eli Lilly, Novo Nordisk Pharm Ltd and Save Medical; KN: Novo Nordisk employee and shareholder; KE and TS: Novo Nordisk employees; SS: Lecture fees from Sumitomo Pharma, Eli Lilly and Novo Nordisk.

: <i>Approval of the research protocol</i>The protocol was approved by the IEC or other appropriate body and provided by each investigator prior to undertaking any study-related activities.<i>Registration number and approval date of registry of the trials:</i> NCT03786406, 26 December 2018, and NCT03811288, 22 January 2019.<i>Human research</i>All procedures followed were in accordance with the ethical standards of the responsible committee on human experimentation (institutional and national) and/or with the Helsinki Declaration of 1964 and later versions. Informed consent was provided by each patient prior to undertaking any study-related activities (during the first and only study visit).